# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person * Guy Wendy				2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
	CESSA P	(First) HARMACE COLA DRIV	(Middle) UTICALS, VE, SUITE 106		nte of Earlies 05/2021	t Tran	saction	ı (Mo	onth/Day	/Year)		X Office	er (give title bel Chief A	ow) Administrativ	Other (species Office		w)
HANOV	ER, MD 2	(Street)		4. If <i>i</i>	Amendment	, Date	Origin	al Fil	ed(Month	/Day/Year)		_X_ Form fil	ual or Joint/O led by One Repo	orting Person		oplicable l	Line)
(City		(State)	(Zip)		Т	able l	- Non	-Deri	vative S	Securities	s Acqu	ired, Disp	osed of, or I	Beneficially	Owned		
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)	Exec any	Deemed cution Date, inth/Day/Yea	f Co (In	Fransac de str. 8)	etion	(A) or l (D)	rities Acc Disposed	of	Beneficia	nt of Securiti Ily Owned F Transaction and 4)	ollowing	Form: Direct	ship of Bo	Nature Indirect eneficial wnership
				(	Code	V	Amoun	(A) or (D)	Price				or Indi (I) (Instr.	,	nstr. 4)		
Common Stock		08/05/2021				A		7,601	A	<u>(1)</u>	184,181	1		D			
Common Stock 08/0		08/05/2021				F		2,254	D	\$ 6.2	181,927	81,927		D			
Common Stock											166,691	691		I		y orLyst, LC	
Reminder:	Report on a s	separate line for	each class of securion		eneficially o		I c	Personta conta	ons wh ained ir orm dis	o respo n this fo plays a	rm are curre	e not requ ntly valid	ction of inf uired to res OMB conf	spond unle	ess	SEC 14	74 (9-02)
	I.				uts, calls, w								l. n		2 40		Lass
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Y	Execution Dat	e, if	Code	of Deri	vative rities nired or osed 0) r. 3,	6. Date Exercisable and Expiration Date (Month/Day/Year)		Amo Und Seco	itle and ount of derlying urities tr. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number Derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	Ow For Der Sec Dir or I	mership m of rivative curity: ect (D) indirect str. 4)	Beneficial	
					Code V	(A)		Date Exerc	cisable	Expiratio Date	n Title	Amount or Number of Shares					

# **Reporting Owners**

			Relationships	
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Guy Wendy C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076			Chief Administrative Officer	

### **Signatures**

/s/ Wendy Guy by Michael B. Kirwan, as Attorney-in-Fact	î	08/06/2021
**Signature of Reporting Person		Date
		J

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vesting of time-based restricted shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.